tirzepatide microdosing schedule with Mounjaro KwikPens | Scott Isaacs, MD, FACP, FACE posted on the topic Microdosing Tirzepatide: What You Need

Diabetes 55 , S70S77 (2006)

After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association

It May Protect Your Brain and Nerves Emerging research suggests GHK-Cu may protect nerve tissue and support brain health, potentially playing a role in cognitive longevity and neurological recovery over time

cDNA was isolated (iScript cDNA synthesis kit